- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.04. | Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges | 1 | Benzinga.com | ||
| 22.04. | Stifel raises Inhibrx Biosciences price target on trial optimism | 2 | Investing.com | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.04. | Stifel verdoppelt Kursziel für Inhibrx Biosciences aufgrund von Studienoptimismus | 2 | Investing.com Deutsch | ||
| 22.04. | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | 644 | AFX News | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 22.04. | Inhibrx cancer drug reportedly drawing interest of Merck and rivals | 3 | Seeking Alpha | ||
| 21.04. | Inhibrx meldet 20 % Ansprechrate für Ozekibart in Darmkrebs-Studie | 3 | Investing.com Deutsch | ||
| 21.04. | Inhibrx reports 20% response rate for ozekibart in CRC trial | 1 | Investing.com | ||
| 17.04. | Stifel reiterates Inhibrx Biosciences stock rating on drug potential | 1 | Investing.com | ||
| 08.04. | Inhibrx gains as Stifel issues new Buy based on lead assets | 2 | Seeking Alpha | ||
| 08.04. | This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday | 3 | Benzinga.com | ||
| 07.04. | Stifel initiates Inhibrx Biosciences stock with buy rating | 2 | Investing.com | ||
| 07.04. | Stifel startet Coverage für Inhibrx Biosciences mit Kaufempfehlung und hohem Kursziel | 2 | Investing.com Deutsch | ||
| 19.03. | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | 524 | PR Newswire | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| 19.03. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Inhibrx Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 23.02. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.12.25 | Why Inhibrx's Recent Strength May Not Be Built to Last | 2 | Benzinga.com | ||
| 17.12.25 | Inhibrx: Citizens bekräftigt "Market Perform"-Rating wegen unzureichender Daten | 11 | Investing.com Deutsch | ||
| 17.12.25 | Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures | 3 | Investing.com | ||
| 17.12.25 | Inhibrx Advances INBRX-106, Ozekibart Programs, Key Milestones Expected Next Year | - | RTTNews |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 34,130 | 0,00 % | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen |
Das Unternehmen INHIBRX BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 129,06 Euro und damit -0,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.